PSMA PET/CT–derived Tumor Volume for Predicting Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177 Lu-PSMA-617

Key Points

• To evaluate the impact of PSMA PET/CT-derived total tumor volume on prediction models for survival and response in metastatic castration-resistant prostate cancer.
• Utilized prostate-specific membrane antigen PET/CT imaging to derive total tumor volume.
• Integrated tumor volume data with existing prediction models.
• Analyzed overall survival, progression-free survival, and biochemical response to 177 Lu-PSMA-617.
• Incorporating tumor volume improves the accuracy of survival prediction models.
• Enhanced discriminatory ability for overall and progression-free survival outcomes.
• Improved predictions for biochemical responses were observed.